TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03006068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib (ABT-494)
Description: Upadacitinib (ABT-494) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib (ABT-494)
Description: Upadacitinib (ABT-494) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib (ABT-494)
Description: Upadacitinib (ABT-494) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib (ABT-494)
Description: Upadacitinib (ABT-494) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT01094652

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole grain diet
Description: Subjects were told to consume three different kinds of study food each day. The goal was an intake of greater than or equal to 80 g of whole grains per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Refined grain diet
Description: The refined grain food products were matched as closely as possible to the foods contained in the whole grain diet. Subjects were told to consume three different kinds of study food each day.
Study: NCT02923245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: point-of-care ultrasound
Study: NCT00648505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glipizide and Metformin HCl Tablets 5 mg/500 mg
Description: 5/500mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metaglip® Tablets 5 mg/500 mg
Description: 5/500mg, single dose fed
Study: NCT03328494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172722
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172722
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172722
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study: NCT00005601

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Study: NCT03910348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-impact exercise
Description: In the high-impact exercise program, the patients were asked to jump using a jump-rope at the beginning of each session
Study: NCT01863641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: Patients will receive calcitriol at a fixed dose of 0.25 µg (one oral pearl) daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Patients will receive placebo similar to intervention (shape, color and design) 1 oral unit daily.
Study: NCT03403621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentamidine Isethionate
Description: Approximately 1.8 mL single dose delivered as topical formulation containing 2% topical pentamidine in silicone-containing base.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active ingredient. Approximately 1.8 mL single dose delivered as topical silicone compounding base only.
Study: NCT00943176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil
Description: 100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.
Study: NCT03066856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: The main aim of the trial is to reduce serum levels of IGF-I and IRm with a a low- calorie and low-protein diet. In humans, calorie restriction alone does not seem to significantly lower IGF-I; protein restriction is also required. In detail, recommendations for participants included in the intervention arm include:~* reducing protein intake, mainly milk and animal protein (except fish), down to 10-12% of total calorie intake.~* reducing high glycemic index food and high insulinemic foods.~* reducing sources of saturated fat (red and processed meat, milk and dairy products).~* eating mostly food of plant origin, with a wide variety of seasonal products.
Study: NCT01038414

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Extended Duration Behavioral Smoking Cessation Counseling
Description: Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extended Duration Behavioral Smoking Cessation Counseling
Description: Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extended Duration Behavioral Smoking Cessation Counseling
Description: Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling
Study: NCT05936541

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium Bifidum PRL2010
Description: Probiotic supplement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: No probiotic supplementation
Study: NCT01229033

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: Ablation of atrial tachycardia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioversion
Description: Cardioversion of atrial tachycardia
Study: NCT02284763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EtCO2
Description: Initial data collection during BCP was performed following three conditions were satisfied: after start of surgery; at least 15 min after BCP (for stabilization of MAP); after ventilation frequency was adjusted to produce EtCO2 of 27-29 mmHg with tidal volume of 8 ml/kg. Data was collected every 3 min after decreasing ventilation frequency by 1-2 breaths/min to increase EtCO2 until 42-45 mmHg. Once the value of EtCO2 42-45 mmHg was reached, ventilator frequency was increased in the same way to decrease EtCO2 until 27-29 mmHg. Fraction of inspired oxygen of 50% was maintained and end-tidal desflurane concentration was adjusted to achieve bispectral index values of 40-55 during data collection.
Study: NCT04112095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norgestrel 0.075 mg tablets
Description: All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 24 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet.
Study: NCT01197170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg by mouth daily of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg by mouth daily of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg by mouth daily of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg by mouth daily of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg by mouth daily of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Starting dose 10 mg by vein on day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Starting dose 5 mg by mouth daily for a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Starting dose 200 mg by mouth twice a day of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Starting dose 75 mg by mouth daily for a 28 day cycle.
Study: NCT01534364

Intervention type: OTHER
Group type: OTHER
Intervention: calorie restriction
Description: Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery)
Study: NCT03866733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continous erector spinea block
Description: Ultrasound guided erector spinea block will be performed while the patient is in left lateral position ) the US probe will be placed in longitudinal parasagittal plane lateral to the T5 spinous process. An 18-gauge epidural needle will be inserted in-plane in a cranial-to-caudal direction until the tip is deep to erector spinae muscle. A 5 cm of epidural catheter will be threaded in cephalad direction. The same steps will be performed on the other side, after the negative aspiration for blood, bolus dose 15 ml of 0.25% bupivacaine will be injected in each of the catheters followed by a continuous infusion of 0.125% plain bupivacaine at the rate of 0.1 ml/kg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous narcotics
Description: intervention: injection of boluses of intra venous Narcotic drugs (fentanyl) in the dose of (1-2mcg/kg) during the surgery after induction of anesthesia then fentanyl infusion through the postoperative first 24 hours postoperative till extubation then intravenous pethidine till 48 hours after surgery.
Study: NCT02472743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-built phototherapy lamp
Description: Described in the arm description
Study: NCT01942031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: structured collegial feed back
Description: Collegial feed back to primary care physicians at randomized primary care centers
Study: NCT03286933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: 75 minute weekly group yoga classes for 8 weeks. Home program online.
Study: NCT04969380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave
Description: The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
Study: NCT03180424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L Carnitine
Description: L Carnitine liquid, single daily dose of 2g orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L Carnitine
Description: L Carnitine liquid, single daily dose of 2g orally.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: Modified Otago exercise programme, 2 times a week with a duration of 45 minutes, to be supervised by a previously qualified and trained instructor. Follow up of the established plan includes an adequate monitoring, evaluating the evolution and the possible adverse effects that may appear.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supervised exercise
Description: Modified Otago exercise programme, 2 times a week with a duration of 45 minutes, to be supervised by a previously qualified and trained instructor. Follow up of the established plan includes an adequate monitoring, evaluating the evolution and the possible adverse effects that may appear.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Liquid substance, similar to the one containing L carnitine, in the same presentation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise at home
Description: A schedule of exercises will be given in the consultation, which the patient will perform at home, without supervision
Study: NCT01201174

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: fermented papaya preparation (FPP)
Description: Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP) at 37oC in humidified atmosphere of 5% CO2 in air (10). Following 5 min centrifugation at 800 rpm, the supernatants will collected for Hb determination by measuring the absorbance at 540 nm.
Study: NCT02073565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrbusNeich Combo stent™
Description: The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus Eluting Stent (EES)
Description: Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
Study: NCT02716493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation program
Description: The intervention was an 8-week home-based telerehabilitation program (three sessions of about 75 minutes per week) using the eChez-Soi telerehabilitation platform.~Through a unique software interface, the eChez-Soi allows for the following three technological aspects: 1- continuous data acquisition and recording from commercial biometric sensors; 2- continuous transmission of the collected data via the Internet to the clinician's computer, allowing the clinician to visualize the biomechanical and physiological parameters in real time; and 3- a challenging gaming environment with interactive exercises performed on musical rhythms.~In total, 15 supervised sessions and 9 unsupervised sessions were planned for a total of 24 exercise sessions
Study: NCT01195844

Intervention type: BIOLOGICAL
Intervention: Rotavirus Vaccine
Description: This is an observational study evaluating hospitalizations and the medical care for the treatment of diarrhea from rotavirus infection in children \< 5 years of age; however, any rotavirus vaccines used in the children presenting with rotavirus-attributed diarrhea were evaluated, as well the prevalent rotavirus serotypes in this sample for future vaccine development.
Study: NCT01789671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based behavioral intervention
Description: This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-based behavioral intervention
Description: This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
Study: NCT03567993

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: Participants randomized to the comparison arm will receive twice-monthly abstinence assessments from the text messaging system, with no motivational feedback. Those in the comparison arm are neither offered nor encouraged to participate in the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants randomized to the intervention arm will receive:~1. Motivational Messages~2. Abstinence and Motivation to Use Services Assessments~3. Encouragement to access the Quitline~4. Encouragement to use Nicotine Replacement Therapy (NRT)~5. Provision of NRT, if requested~Intervention subjects are encouraged to access the Quitline and use NRT. However, these are not mandatory components of the intervention and subjects can choose if they would like to engage with the Quitline or use NRT.
Study: NCT05138484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: experimental group 10% mouthwash of M. sylvestris extract
Description: To each patient was delivering a 150 ml bottle with the corresponding mouthwash. The indications for posology were: rinse with 10 ml of mouthwash for 1 minute in the mouth, every 12 hours for 7 days. To the follow-up of the intervention, was made telephone calls at least once a day to remember the rinse.
Study: NCT02962323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Rosuvastatin Calcium Tablets 40 mg
Description: Oral, crossover

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA
Description: Oral, crossover
Study: NCT03724240

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: 4 x 2 injection over 21 days the dosage is100 µg/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: 4 x 2 injection over 21 days the dosage is100 µg/ml
Study: NCT01752894

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angio-guided PCI with EES or BES
Description: Angio-guided intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI with EES or BES
Description: OCT-guided intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with BES under angio-guide or OCT guide
Description: biolimus A9-eluting stent.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI with EES under angio-guide or OCT guide
Description: everolimus eluting stent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keep DAPT
Description: maintain DAPT for 12 months according to level of uncovered strut (\>6%) at 3months OCT follow up after stent implantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Discontinue DAPT
Description: discontinue DAPT according to level of uncovered strut (≤6%) at 3months OCT follow up after stent implantation.
Study: NCT03424629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose UC-MSCs
Description: Participants will receive 6 times UC-MSCs infusions (each time 1×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose UC-MSCs
Description: Participants will receive 6 times UC-MSCs infusions (each time 3×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Participants will be administered Methotrexate (each time 5-25mg) orally once a week for successive 16 weeks(week 0-15).
Study: NCT03945097

Intervention type: BEHAVIORAL
Intervention: preK
Description: Subjects enter and education program that either focuses on learning letters and their corresponding sounds or on language comprehension skills.
Study: NCT00925288

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: Dosage Form: 0.5 ml intramuscular injection Dosage: Gardasil 0.5ml suspension Frequency: 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: Dosage Form: 0.5 ml intramuscular injection Dosage: Gardasil 0.5ml suspension Frequency: 3 doses
Study: NCT00088452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethosuximide
Description: Ethosuximide is a common treatment for childhood absence epilepsy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine is a common treatment for childhood absence epilepsy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic acid
Description: Valproic acid is a common treatment for childhood absence epilepsy.
Study: NCT04549142

Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention

Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention

Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention

Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention
Study: NCT02596399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSTA4637S
Description: Participants will receive DSTA4637S intravenously on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to DSTA4637S intravenously on Day 1.
Study: NCT02007759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitalStim
Description: This group will receive active VitalStim treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VitalStim
Description: This group will receive a sham VitalStim intervention.
Study: NCT02476708

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin 1800mg
Description: Curcumin, derived from turmeric root, is an over-the-counter supplement which is tolerated well.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo capsule
Study: NCT03138746

Intervention type: PROCEDURE
Intervention: HBO
Description: Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow oxygen for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes

Intervention type: PROCEDURE
Intervention: Hyperbaric air
Description: Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow air for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes
Study: NCT00800956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-esreboxetine
Description: Single oral dose of 6mg esreboxetine in solution containing approximately 100uCi \[14C\]-esreboxetine
Study: NCT00664456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant therapy
Description: AHT group receives 9 cycle of LHRH-A (goserelin acetate 3.6 mg/4 weeks or leuprorelin acetate 3.75 mg/4 weeks) after Iodine I-125 implantation (TPPB).
Study: NCT03035006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipotecan
Description: Lipotecan based concurrent chemoradiotherapy